Ranbaxy Laboratories has received tentative approval from the US Food and Drug Administration (USFDA) to manufacture and market Lamivudine tablets in 150 mg strength, the company announced today.This is the first product reviewed under the expedited review provisions of the US president's emergency plan for aids relief (Pepfar) programme. In combination with other antiretroviral agents, Lamivudine tablets are for the treatment of HIV infection."We are pleased and proud of our achievement in being granted USFDA tentative approval for Lamivudine. This formulation now qualifies as our first product to be included among a portfolio of drugs to be associated with the Pepfar initiative. We will continue to add products to this program to help patients afflicted with HIV aids. The Ranbaxy global organization is committed and dedicated to this humanitarian effort," said Brian W Tempest, CEO and MD, Ranbaxy Laboratories.
